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Maladaptive inflammation is amajor suspect in progressive neurodegeneration, but the underlyingmechanisms are difficult to envisage
in part because reactive glial cells at lesion sites secrete both proinflammatory and anti-inflammatory mediators. We now report that
astrocytes modulate neuronal resilience to inflammatory insults through the phosphatase calcineurin. In quiescent astrocytes, inflam-
matorymediators suchas tumornecrosis factor- (TNF-) recruits calcineurin to stimulate a canonical inflammatorypathway involving
the transcription factors nuclear factor B (NFB) and nuclear factor of activated T-cells (NFAT). However, in reactive astrocytes, local
anti-inflammatory mediators such as insulin-like growth factor I also recruit calcineurin but, in this case, to inhibit NFB/NFAT. Proof
of concept experiments in vitro showed that expression of constitutively active calcineurin in astrocytes abrogated the inflammatory
response after TNF- or endotoxins and markedly enhanced neuronal survival. Furthermore, regulated expression of constitutively
active calcineurin in astrocytes markedly reduced inflammatory injury in transgenic mice, in a calcineurin-dependent manner. These
results suggest that calcineurin forms part of a molecular pathway whereby reactive astrocytes determine the outcome of the neuroin-
flammatory process by directing it toward either its resolution or its progression.
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Introduction
Inflammation, a common denominator among the diverse list of
neurodegenerative diseases, has been implicated recently as a key
mechanism responsible for the progressive nature of neurode-
generation (Minghetti, 2005). As a result of a low turnover rate
and little ability to recover from injury, neurons are extremely
vulnerable to self-destructive inflammatory processes. This
might hinder the recovery of neurological function at sites of
inflammation or even exacerbate neuronal injury through a
pathological cascade. The hallmark of brain inflammation is the
activation of glial cells (Ridet et al., 1997). These cells constitute
essential partners of neurons, providing functional support
through amyriad of intercellular links (Seifert et al., 2006). How-
ever, during inflammation, glial cells may play a double-edged
role because, depending on the course of the inflammatory pro-
cess, glial-derived factors may result in being either beneficial or
detrimental to neurons (Wyss-Coray and Mucke, 2002). There-
fore, a balance between proinflammatory and anti-inflammatory
signaling arising from a diversity of cells within the affected brain
area will eventually determine the outcome of the inflammatory
process. If the proinflammatory cascade, mounted mostly by ac-
tivated microglia and astrocytes, is harnessed, the neuroprotec-
tive signals that these two types of glial cells produce, together
with those produced by endothelial cells and neurons, will tilt the
balance toward resolution of the process. Although the proin-
flammatory function of astroglia is usually considered not to be
as prominent as that of microglia (Streit et al., 1999), astroglia
become activated in response to immunologic challenges or brain
injuries (Seifert et al., 2006). In fact, reactive astrogliosis is a
marker of brain damage in general (Ridet et al., 1997). At the
same time, activated astrocytes provide support for damaged
neural tissues through several mechanisms, including release of
neurotrophic factors and downregulation of proinflammatory
messengers (Wyss-Coray andMucke, 2002). However, the cellu-
lar and molecular pathways underlying interactions between
proinflammatory and anti-inflammatory signaling within brain
tissue are not well delineated.
While analyzing the anti-inflammatory actions of insulin-like
growth factor I (IGF-I), a potent neuroprotective signal upregu-
lated in all types of brain lesions (Torres-Aleman, 2000), we ob-
served that inhibition of IGF-I expression at inflammatory sites
exacerbated astroglial reactivity (Fernandez et al., 1997). This
effect was probably related to the antagonistic actions of IGF-I on
tumor necrosis factor- (TNF-) signaling onto astrocytes, an
effect in which the phosphatase calcineurin appears to be in-
volved (Pons and Torres-Aleman, 2000). In turn, TNF- partic-
ipates in glial-mediated inflammation through activation of the
canonical nuclear factor B (NFB) pathway (Ginis et al., 2002).
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In the present work, we explored proinflammatory and anti-
inflammatory pathways in astrocytes and their significance in
neuronal demise and found that calcineurin plays a dual role in
inflammatory responses.
Materials andMethods
Materials. Human IGF-I was from GroPep (Adelaide, Australia), bacte-
rial lypopolysaccharide (LPS) and rat TNF- were both from Sigma (St.
Louis, MO), the proteasome inhibitor MG-132 (carbobenzoxy-L-leucyl-
L-leucyl-L-leucinal), an IGF-I receptor antagonist [picropodophyllin
(PPP)], and the calcineurin inhibitor cyclosporine A (CsA) were pur-
chased from Calbiochem (Darmstadt, Germany). Antibodies against ac-
tivated caspase 3 (a marker of apoptotic cells; 1:1000; Cell Signaling
Technology,Danvers,MA),3-tubulin (a neuronalmarker; 1:5000; Pro-
mega,Madison,WI),GFAP (an astrocytemarker; 1:1000; Sigma),OX-42
(a microglia marker; 1:400; Serotec, Oxford, UK), A2B5 (an oligoden-
droglia marker; 1:500; Serotec), major histocompatibility complex II
(MHCII) (1:300; Serotec), CD11b (1:500; Serotec), calcineurin (1:1000:
Chemicon, Temecula, CA), -actin (1:2000; Sigma), superoxide dis-
mutase (SOD) Cu/Zn (1:2000; Stressgen, San Diego, CA), inducible ni-
tric oxide synthase 2 (iNOS2) (BD Transduction Laboratories, San Di-
ego, CA), cyclooxygenase 2 (Cox2) (CaymanChemical, Ann Arbor,MI),
IGF-I (GroPep), NFBp65, nuclear factor of activated T-cells (NFAT4),
GATA3, peroxisome proliferator-activated receptor  (PPAR), and
ubiquitin (all from Santa Cruz Biotechnology, Santa Cruz, CA), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Affinity BioRe-
agents, Golden, CO) were all used at a 1:1000 dilution except when
indicated otherwise. Secondary antibodies were goat anti-rabbit or
mouse HRP-coupled (1:20,000; Bio-Rad, Hercules, CA) or Alexa-
coupled (1:1000; Invitrogen, Carlsbad, CA).
Generation of transgenic mice. Regulated expression of a truncated,
constitutively active form of calcineurin (CnA) in astrocytes was
achieved with the “Tet-off” system by generating two transgenic mouse
lines. A first mouse line expressed tet-transactivator (tTA) under the
astrocyte-specific GFAP promoter (pGFAP). A 1.8 kb of the murine
pGFAP was cloned from genomic tail DNA using primers 5 CTGT-
GAACTCGAGACCTGCTT 3 and 5 TCTCCGCTGAATTCTGC-
CCTGC3 that also generated the sites 5XhoI and 3 EcoRI, respectively.
The pGFAP was placed upstream of a XhoI–EcoRI fragment coding for
tTA (pTet-off vector; Clontech, Mountain View, CA). The pGFAP–tTA
fragment was cut from the vector by digestion with XhoI andHindIII. A
second transgenic line expressed CnA under the control of the tTA-
sensitive TetO promoter. A cDNA encoding a truncated form of the
murine calcineurin catalytic subunit A, CnA (O’Keefe et al., 1992),
was placed downstream from the TetO promoter (from pTRE vector;
Clontech). The TetO promoter–CnA fragment was cut from the vector
with XhoI and HindIII. The pGFAP–tTA and TetO–CnA DNA frag-
ments were purified and independently injected into fertilized eggs of
C57BL/6/SJL mice. Founder mice were analyzed by Southern blotting
and PCR as described previously (Fernandez et al., 2001), using specific
primers and backcrossed to C57BL/6 mice to generate the lines pGFAP–
tTA (GFAP) and TetO–CnA (CnA). To generate the double-mutant
mice [herein called astrocyte inducible calcineurin (AIC) mice], line
GFAP7 (F3 generation) was crossed with line CnA5 (F3 generation).
Mice had access to food and plain water ad libitum or water comple-
mented with doxycycline (Dox) (2 mg/ml; Sigma). Animals were kept
under light/dark conditions following European Union guidelines (Di-
rective 86/609/EEC) and handled according to institutionally approved
procedures.
In vivo experiments. AIC mice underwent brain injury following pro-
cedures described previously (Lopez-Lopez et al., 2004). Briefly, cortical
stab wounds were performed in deeply anesthetized (2,2,2 tribromoeth-
anol; Sigma) mice receiving (Dox) or not doxycycline (Dox) in their
drinking water during 1 week before insult to control astrocyte expres-
sion of CnA. A 26 gauge needle was inserted 3 mm from the surface of
the brain (1.3–1.4 mm caudal to bregma, 1.5 mm lateral). Animals were
allowed to survive for 5, 10, 20, 30, and 60 d. In a second group of
experiments, AIC mice were treated with Dox for 1 week and submitted
to brain injury. Two days later, Dox treatment was discontinued in a
subset of animals, and the effect of delayed CnA expression was deter-
mined 5 d after injury. Another group of animals treated for 1 week with
Dox received an LPS injection (Escherichia coli serotype 055:B5; 0.5
g/2 l sterile pyrogen-free saline; Sigma) in the parietal cortex over 2
min with a Hamilton syringe at the following coordinates: 1.3 mm an-
teroposterior, 1.5 mm lateral, and 1 mm dorsoventral. Animals were
allowed to survive for 1, 3, and 10 d. A second group of AIC mice also
treated for 1 week before inflammatory challenge with or without Dox
received a single intraperitoneal injection of LPS (1 mg/kg, in 100 l
vehicle) or vehicle solution. Animals were allowed to survive for 1 and
5 d. To determine perilesion changes, inflammatory markers and neuro-
nal death were determined by Western blot (WB) and immunofluores-
cence. For biochemical studies, a block of brain parenchyma surround-
ing the stab wound or injection site (2 mm wide, 4 mm high) was
dissected from each animal. Ten animals per group were used.
In vitro experiments. Pure astroglial cultures [95% GFAP-positive
(GFAP), OX-42-negative (OX-42), A2B5 cells] were prepared as
described previously (Pons and Torres-Aleman, 2000). Briefly, postnatal
(day 3–4) brains were dissected and immersed in ice-cold DMEM/F-12;
Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum
(FBS). Cortex andhippocampuswere removed and cut into 1mmpieces.
Tissue fragments were dissociated mechanically, and the resulting cell
suspension was centrifuged (1000 rpm/10 min) and plated in DMEM/
F-12 with 10% FBS, 5 105 cells per well. Cerebellar granule cells from
7-d-old rats were grown in plates covered with poly-L-lysine and Neuro-
basal plus B27 (Invitrogen), glutamine, and 25 mM KCl. Under these
conditions,95% of the cells are neurons (3-tubulin). Neurons were
plated at 1  106 cells per well. Astrocyte–neuron cocultures were pre-
pared as follows: astrocytes were plated, and, when they were 70% con-
fluent, the medium was removed and neurons were plated onto them
with freshly added medium. Cultures were allowed to grow for 4 d. In
time course experiments with transfected neuronal cultures or neuron–
astrocyte cocultures, cells were treatedwith cytotoxic doses of LPS (E. coli
serotype 0127:B8; 1g/ml; Sigma) or TNF- (20 ng/ml) for up to 72 and
24 h, respectively. The schedule of the experiments in transfected cocul-
tures is detailed in Figure 1B. The calcineurin inhibitor CsA (500 nM)was
added to transfected astrocytes 24 h before plating the neurons to avoid
inhibition of neuronal calcineurin (see Fig. 1B). The proteasome inhib-
itor MG-132 (1 M) was added 1 h before LPS or TNF- stimulation of
cocultures (see Fig. 1B). Cultured cells were transfected using Fugene
reagent (Roche, Basel, Switzerland) when 70% confluent. Plasmids
transfected were as follows: pGFAP–tTA (GFAP) and TetO–CnA
(CnA); pNFB–secreted alkaline phosphatase (SEAP) or pNFAT–
SEAP and pCMV–CnA. Mock transfection was done with pCMV
vector.
In experiments using wild-type (wt) cultures, cells were exposed for
16 h to LPS or for 3 h to TNF- before adding IGF-I (100 nM), and cell
death was assessed 2 h later.When investigating the role of calcineurin in
IGF-I neuroprotection in wt cells, CsA was added 1 h before IGF-I. In
experiments using cells obtained fromAICmice, doxycycline (10g/ml)
was added to the cultures at the same time that astrocytes were plated to
inhibit CnA expression from the onset of the experiment.
In vitro assays. Production of reactive oxygen species (ROS) was de-
termined by analyzingH2O2 levels in the cultures as described previously
(Brera et al., 2000), with minor modifications. Briefly, the method uses
the nonfluorescent cell-permeant compound 2,7-dichlorofluorescein
diacetate (Invitrogen) which can be oxidized by peroxides producing the
fluorescent compound 2,7-dichlorofluorescein. Generation of perox-
ides was measured in a FLUOstar plate reader (BMG Lab technologies,
Offenburg, Germany) at an excitation wavelength of 485 nm and an
emission of 520 nm.
To measure the activity of the transcription factors NFB and NFAT,
we used the SEAP reporter system that determines the levels of enzymat-
ically active SEAP. Assays were performed according to the protocol of
the manufacturer (Clontech). Transient transfections were performed
with 250 ng of the plasmids pNFB–SEAP and pNFAT–SEAP, and, after
24 h, luminescence was quantified using a Sirius Luminometer (Berthold
Detection Systems, Pforzheim, Germany).
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Calcineurin activity was determined using a
calcineurin activity kit (Calbiochem). Culture
cells andmouse brain tissue were homogenized
in lysis buffer (50 mM Tris, 1 mM DTT, 100 M
EDTA, 100 M EGTA, and 0.2% NP-40, pH
7.5) and protease inhibitor cocktail (Roche). To
remove free phosphate, supernatant extracts
were added to a desalting column resin. Phos-
phatase assays were performed in a total of 100
l in assay buffer (200 mM NaCl, 100 mM Tris,
12 mM MgCl2, 1 mM CaCl2, 1 mM DTT, and
0.05% NP-40, pH 7.5). Recombinant human
calcineurin at 50 U/l, 25 M calmodulin, and
10 l RII phosphopeptide were used per assay.
When indicated, EGTA was added (20 mM),
and assays were incubated at 30°C for 30 min.
Calcineurin phosphatase activity was measured
by luminescent detection at 620 nm of free
phosphate released from the calcineurin-
specific RII phosphopeptide using the green re-
agent. Assays were performed in duplicate at
each time point in three separate experiments.
Reverse transcription-PCR was performed
using the QuantumRNA Universal 18S system
fromAmbion (Austin, TX). Total RNAwas iso-
lated from cultured cells or mouse tissues using
Trizol (Invitrogen). Equivalent amounts of to-
tal RNA served as template for cDNA synthesis
using M-MLV (Moloney murine leukemia vi-
rus) reverse transcriptase (Promega) at 42°C,
followed by PCRusing specific primers directed
to the 3 end of the GFAP promoter and the 5
end of CnA: forward, 5 GATGTGCTTTAC-
TAAGTCATC 3; and reverse, 5 CAGT-
TCATCGTCGGAGCAGA 3. RNA 18S was
quantitated as a loading control.
For RNA interference experiments [Silencer
small interference RNA (siRNA) transfection II
kit; Ambion], three different double-stranded
CnA siRNAs (with sequences CnA1, 5 GGAA-
GUGUUUGAUAACGAU3; CnA2, 5GGAAG-
GCAGGCUGGAAGAA 3; CnA3, 5 GGAUU-
CUCACCACAACAU 3) were transfected (30
nM) with siPORTNeoFX (Ambion) into primary
astrocytes (12-well plates containing 9  104
cells/ml). Seventy-two hours later, cultures were
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Figure1. Astrocytic calcineurin andneuroinflammatory damage.A, Astrocytes transducedwithCnA show increased activity
of calcineurin (measured as release of PO4) compared with mock-transfected (CMV) or wt astrocytes (histograms). OnlyCnA-
transfected astrocytes produced the truncated mutant form of calcineurin (CnA; blots). Levels of endogenous calcineurin
remained unaffected. B, Schedule followed for coculture of astrocytes and neurons. Astrocytes were plated and transfected with
corresponding DNAs, and neurons were added 24 h later. Thereafter, cocultures were challengedwith inflammatory stimuli (LPS
4
or TNF-) for various times before analysis of neuronal death
after a total of 4 d in coculture. Inhibitors such as CsA or MG-
132 were added at indicated times. C, Photomicrographs,
Representative double immunocytochemical staining used to
identify apoptotic (activated caspase 3 cells; red) neurons
(3-tubulin cells; green) after inflammatory challenge.
Histograms, Neurons cocultured with mock-transfected as-
trocytes (CMV; striped left histograms) die soon after LPS (top
histograms) or TNF- addition (bottom histograms),
whereas when cocultured with astrocytes expressing CnA
(black right histograms), they show a significantly greater re-
sistance to these inflammatory stimuli (**p	0.01 vs respec-
tive CMV times). Number of living neurons are expressed as
percentage of unstimulated control cultures at time 0. Scale
bar, 100m. D, The release of ROS in response to proinflam-
matory stimuli (LPS or TNF-) was fully abrogated when as-
trocytes (butnotneurons) expressedCnAbutnot theempty
vector (CMV). Note that, with the doses of LPS or TNF- used,
astrocytes did not produce ROS. All experiments were re-
peated six times. ***p	 0.001.
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stimulatedwithLPS(1g/ml)overnight.Cellswere lysed, and levelsofCnA,
iNOS2, Cox2, GAPDH (as a siRNA internal control), and -actin were de-
termined byWB. A nontargeting siRNA and aGAPDH siRNAwere used as
negative and positive controls, respectively. Assays were performed in
triplicate.
Immunofluorescence. Immunocytochemistry was performed as de-
scribed previously (Trejo et al., 2001). Animals (n
 10 per group) were
deeply anesthetized with pentobarbital (50 mg/kg) and perfused tran-
scardially with 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4
(PB). Coronal 40-m-thick sections were cut in a vibratome and col-
lected in PBS. For in vitro experiments, cells were plated on 20 mm
coverslips and fixed. Coverslips or free-floating brain sections were
blocked with 5% normal horse serum and incubated overnight at 4°C
with the respective primary antibody in PB containing 0.1% bovine al-
bumin, 3% horse serum, and 0.2% Triton X-100. After several washes in
PB, sections were incubated with an Alexa-coupled secondary antibody
(1:1000). Omission of primary antibody was used as control. Neuronal
death was determined by a single investigator in uncoded brain sections
and cultures, as described (Fernandez et al., 1998). 3-Tubulin/acti-
vated caspase 3 double-stained cells were scored and expressed as per-
centage of total 3-tubulin cells. Activated caspase 3 neurons were
scored in six consecutive sections in a 1 mm2 area or in six different
microscope fields for each coverslip when counting cell cultures. MH-
CII and CD11b cells in double-stained brain sections from lesioned
areas were scored and expressed as number of cells per squaremillimeter.
Confocal analysis was performed in a Leica (Bensheim, Germany)
microscope.
Immunoassays. Animals were perfused transcardially with saline be-
fore collection of brain samples for biochemical analysis. Cells or cerebral
cortex pieces (1 mm around lesion or injection) were homogenized in
ice-cold buffer consisting of 20mMTris HCl, 150mMNaCl, 5mMEDTA,
10% glycerol, 1% NP-40, 400 M sodium orthovanadate, and protease
inhibitors (200 mM PMSF, 1 g/ml aprotinin, and 1 g/ml leupeptin).
WB and immunoprecipitation were performed as described previously
(Pons and Torres-Aleman, 2000). WB membranes were reblotted with
either the same antibody used for immunoprecipitation or with -actin
as internal standards and to normalize for protein load. Levels of the
protein under study were expressed relative to protein load in each lane.
Densitometric analysis was performed using Quantity One software
(Bio-Rad). IGF-I was quantified in cell lysates and media by sandwich
ELISA using mouse IGF-I as a standard (IBT, Reutlingen, Germany).
Briefly, 96-well plates were covered with amonoclonal anti-mouse IGF-I
antibody (1:1000; R & D Systems, Minneapolis, MN) at 4°C overnight.
After several washes with PBS, pH 7.4, wells were incubated with a block-
ing solution containing PBS, pH 7.4, 5% Tween 20, 5% sucrose, and
0.05% sodium azide, 2 h at room temperature. After three washes with
PBS, pH 7.4, plates were placed at 4°C overnight. Samples were added
and maintained at 4°C overnight. After washes, plates were incubated
with a biotinylated anti-mouse IGF-I antibody (1:1000; R & D Systems)
at 4°C overnight. After washes, plates were incubated with a streptavidin
horseradish peroxidase conjugate (1:20,000; GE Healthcare, Little Chal-
font, UK). After washing, o-phenyllenediamine dihydrochloride (Sigma)
was added during 30 min at room temperature. Absorbance was mea-
sured in a spectrophotometer at 450 nm.
A protein array (1.1; Raybiotech, Norcross, GA) to quantitate relative
expression of 40 different inflammation-related factors was used follow-
ing the instructions of themanufacturer.Membraneswere blocked for 30
min and incubated with 50g of AIC astrocyte culture lysate or with 500
g of AIC tissue homogenate for 2 h at room temperature and then
washed for 30 min and incubated with a biotin-conjugated antibody
(1:250) for 2 h. After consecutive washes, streptavidin-conjugated per-
oxidase (1:1000) was added for 1 h at room temperature. Membranes
were washed thoroughly and exposed to ECL substrate (GE Healthcare),
followed by apposition of the membranes with autoradiographic film
(GE Healthcare) for 1 min. The film was scanned, and spots were digi-
tized into pixel densities using the Quantity One imaging software (Bio-
Rad). The ratio of relative expression was established after subtraction of
the background intensity and comparison with the positive spots avail-
able in the membrane.
Figure 2. Regulated expression ofCnA in astrocytes.A, Coexpression of GFAP–tTA (GFAP)
and TetO–CnA (CnA) in cultured wt astrocytes allows Dox-regulated activation of cal-
cineurin. Both control (wt) and GFAP–tTA-transduced astrocytes show lower and Dox-
independent calcineurin activity. ***p	 0.001. B, Astrocyte inducible calcineurin (AIC mouse
5) but not single mutant TetO–CnA or GFAP–tTA mice producedCnA protein, a truncated
form of the wt protein. Wild-type calcineurin (CnA) was detected in the three animals. C, Cal-
cineurin activity in brain extracts from AIC mice (lines 5, 7) was markedly elevated compared
with awt control andwas regulated byDox . ***p	 0.001.D, Expression ofCnAmRNA in the
brain of AICmicewas foundpostnatally andmaintained thereafter. E,CnAmRNA levels in the
brain of AIC mice were inhibited within hours after addition of Dox to the drinking water. F,
Expression ofCnA protein in astrocytes obtained from AIC mice was regulated by Dox in the
culture medium. Controls are astrocytes from wt mice. G, Astrocytes from AIC mice secrete
Cu/Zn SOD (SOD) to themedium after LPS challenge in a calcineurin-dependentmanner. In the
presence of Dox in the culture medium (which suppresses CnA expression), levels of SOD
remain unaffected. Note that expression ofCnA is sufficient to increase SOD levels. Represen-
tative blot is shown (n
 6).H, AIC astrocytes also secrete greater amounts of IGF-I after LPS in
the absence of Dox in the culture medium (*p	 0.05 vs control and **p	 0.01 vsDox and
vs control; n
 6).
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Statistics. Statistical analyses were performed
with a t test when comparing two groups and a
two-way ANOVA for comparing multiple
groups. Statistical significance was established
when p	 0.05. Results shown aremean SEM.
Results
Calcineurin participates in astrocyte-
mediated neuroprotection against
inflammatory damage
As mentioned above, we previously found
that the phosphatase calcineurin mediates
the anti-inflammatory effects of IGF-I on
astrocytes (Pons and Torres-Aleman,
2000). To gain additional insight into the
biological significance of this anti-
inflammatory activity, we transfected wt
rat astrocytes with a constitutively active
form of the catalytic subunit of calcineurin
(CnA). Transfected astrocytes showed
high levels of CnA together with marked
increases in calcineurin activity (Fig. 1A).
Next, we tested the neuroprotective activ-
ity of CnA-transfected astrocytes against
inflammatory damage. When rat cerebel-
lar neurons were cocultured with mock-
transfected astrocytes [cytomegalovirus
(CMV)-transfected astrocytes] and sub-
mitted to TNF- or LPS challenge, they
died within 24–72 h, respectively (Fig. 1C,
left histograms). However, when neurons
were coculturedwith astrocytes expressing
CnA, neuronal death after either LPS (1
g/ml) or TNF- (20 ng/ml) was mark-
edly abrogated (Fig. 1C, right histograms)
( p	 0.01 vs CMV-transfected astrocytes).
Neuroprotection was mediated at least in
part by humoral factors because condi-
tioned medium from CnA-expressing
C
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Figure 3. Astrocytic calcineurin protects against inflammatory damage after brain trauma. A, In AIC mice expressingCnA
(not treated with Dox), the number of dying neurons (3-tubulin-activated caspase 3 cells) 5 d after the lesion in the area
surrounding a traumatic injury (asterisk) of the parietal cortex was reduced compared with AIC mice treated with Dox for 1 week
before lesion. Scale bar, 50m. B, Expression ofCnA in AIC mice (Dox) reduced the number of reactive astrocytes (GFAP;
green) expressing Cox2 (red) in the lesioned area (asterisk). Note expression of Cox2 also by unidentified GFAP cells
4
surrounding the lesion site. Scale bar, 100 m. C, Levels of
both Cox2 and iNOS2 at the injury site were also dramatically
reduced in CnA-expressing AIC mice ( p 	 0.001 vs AIC
Dox, for both markers; n
 10 at 5 d after lesion). Control,
Sham operated; Inj, brain injury.D, Levels of MHCII (a marker
of microglia activation) were increased at the lesion site 5 d
after brain trauma in AIC mice not expressingCnA (Dox;
n
10), but the increasewas smallerwhenexpressingCnA
(Dox;n
10). Protein load ingelswasnormalizedbymea-
suring -actin levels. Bottom histograms, Number of MH-
CII, CD11b (a marker of infiltrating macrophages), and
double MHCII–CD11b cells at the lesioned site in AIC
mice treated with Dox 1 week before lesion (Dox), not
treated with Dox (Dox), or treated with Dox until 2 d after
the lesion (Dox). In the absence of Dox, whenCnA is ex-
pressed in astrocytes, the number of MHCII and MHCII–
CD11b cells is significantly reduced, whereas CD11b cells
remain unaffected. Note that the reduction is also present
when AIC mice started to express CnA 2 d after the lesion
was produced (***p	 0.001 vsDox andDox; n
 5 per
group). Photomicrographs, Representative MHCII and
CDb11 cells located in the vicinity of the lesion site (aster-
isk). Cell counts were done in double-stained brain sections.
Scale bar, 50m.
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astrocytes protected neurons against inflammatory damage
after 16 h of exposure to LPS (36  4% of neurons alive in
conditioned medium from CnA astrocytes vs 1 1.2% neu-
rons alive in conditioned medium from CMV astrocytes; p 	
0.05) or 3 h after TNF- (data not shown). This protective
action was not observed when neurons themselves expressed
CnA (supplemental Fig. 1A, available at www.jneurosci.org
as supplemental material). At the doses used, LPS or TNF-
did not affect astrocyte survival (data not shown). In addition,
when calcineurin activity was inhibited in CnA-expressing
astrocytes by adding the calcineurin inhibitor CsA 24 h before
coculturing them with neurons, neuroprotection against LPS
or TNF- (data not shown) was significantly diminished
(72 5% of neurons alive compared with 35 5% alive when
CsA was added; p	 0.05). Furthermore, neuronal production
of ROS in response to LPS or TNF- challenge was completely
abrogated when neurons were cocultured with CnA-
expressing astrocytes but not when neurons were cultured
alone or with mock-transfected astrocytes ( p	 0.001 vs CMV
transfected) (Fig. 1D).
Astrocyte calcineurin protects against brain
inflammatory injury
We next designed in vivo“proof-of-concept” experiments to es-
tablish an anti-inflammatory action of calcineurin in astrocytes.
Double transgenic mice with Dox-regulated expression of CnA
in astrocytes were generated by crossbreeding mice expressing a
murine GFAP promoter-driven tTA transgene with mice ex-
pressing a TetO-driven CnA transgene. We first corroborated
that in vitro expression of these transgenes allowed Dox-
regulated calcineurin activity in wt astrocytes cotransfected with
them (Fig. 2A). In vivo, double transgenic AIC mice expressed
CnA in the brain (Fig. 2B) and markedly enhanced calcineurin
activity in a Dox-regulatedmanner (Fig. 2C). Detailed character-
ization of AIC mice confirmed the expression of the two trans-
genes (GFAP–tTA and TetO–CnA) (supplemental Fig. 1B,
available at www.jneurosci.org as supplemental material), ex-
pression of CnA mRNA in the brain (supplemental Fig. 1C,
available at www.jneurosci.org as supplemental material), and
Dox-regulated calcineurin immunoreactivity in astrocytes (sup-
plemental Fig. 1D, available at www.jneurosci.org as supplemen-
tal material). Expression of CnAmRNA in AIC brain appeared
early after birth and was maintained thereafter (Fig. 2D).
Importantly, when AIC mice received Dox in the drinking
water, CnA mRNA was inhibited within 24–48 h (Fig. 2E).
Because expression of CnA in cultured AIC astrocytes was also
inhibited by adding Dox (10 g/ml) at the onset of the culture
(Fig. 2F), we concluded that calcineurin activity inAIC astrocytes
was regulated byDox in vivo and in vitro. That calcineurin activity
is regulated by Dox was indirectly confirmed by the observation
that Dox regulated the release by AIC astrocytes of humoral neu-
roprotective signals such as Cu/Zn SOD or IGF-I that are known
to be functionally associated with calcineurin (Tokheim and
Martin, 2006; Alfieri et al., 2007). Thus, in response to proinflam-
matory challenge with LPS, AIC astrocytes secreted larger
amounts of SOD and IGF-I when cultured without Dox (Fig.
2G,H). Similar results were obtained in wild-type rat astrocytes
transduced with CnA and challenged with LPS (supplemental
Fig. 1E, available at www.jneurosci.org as supplementalmaterial)
or TNF- (data not shown), respectively. When the IGF-I recep-
tor antagonist PPP (120 nM) was added to LPS-stimulated cocul-
tures containing CnA-expressing astrocytes, the neuroprotec-
tive action of astrocytes was moderately reduced: 70% of the
neurons were alive in CnA-expressing astrocyte cocultures,
whereas after adding PPP, 60% of neurons were alive. How-
ever, in cocultures with mock-transfected astrocytes, the pres-
ence of PPP reduced to 50% the neuronal survival induced by
astrocytes after LPS insult (from30 to15% neurons alive).
Once we observed that calcineurin protects neurons against
inflammatory death in vitro, we explored whether calcineurin in
AIC astrocytes protected neurons against brain inflammation in
vivo. AIC mice submitted to a penetrating brain injury that pro-
duces an inflammatory response in the lesioned area were ana-
lyzed 5, 10, 20, 30, and 60 d later. At 60 d, weak glial reactivity was
still present in AICmice not expressingCnA, but the rest of the
changes analyzed were resolved within 1 month. Because all
pathological changes examined peaked within 5–10 d of the le-
sion, we analyzed them in detail 5 d after the lesion. In AIC mice
with suppressedCnA expression by treatment withDox (Dox
AIC mice), neuronal death (identified as double-stained 3-
tubulin-activated caspase 3 cells) 5 d after brain injury was
prominent (Fig. 3A). Dox-treated AICmice also showed reactive
astroglial cells (GFAP cells) in the lesion site. These reactive
astrocytes abundantly expressed proinflammatory markers such
as Cox2 (Fig. 3B,C) and iNOS2 (Fig. 3C). In addition, Dox-
treated AIC mice show detectable levels of the reactive microglia
markerMHCII, as well as the presence ofMHCII and CD11b
cells in the lesioned area (Fig. 3D). Notably,MHCII levels, as well
as MHCII and double-stained MHCII/CD11bcells, but not
CD11b cells that remained elevated, were significantly attenu-
ated in AIC mice expressing CnA before injury ( p 	 0.001 vs
Dox AIC mice; n 
 10) (Fig. 3D, Dox) (supplemental Fig.
2A, available at www.jneurosci.org as supplemental material). At
5 d after lesion, the number of apoptotic neurons in the lesioned
area was significantly decreased when CnA was expressed:
Table 1. Increases in proinflammatorymediators after inflammatory challenge
(brain trauma or LPS) in AIC mice with blockedCnA expression (with Dox) or in
LPS- challenged astrocytes obtained from AICmice and cultured with Dox
compared with those expressingCnA (without Dox).
Cytokine Brain trauma Brain LPS In vitro LPS
BLC 5 4 2
Eotaxin 5 4 2
GM-CSF 5 4 2
IFN 5 4 2
IL-1 4 4 3
IL-1 4 4 3
IL-2 4 4 3
IL-3 4 4 3
IL-4 4 4 3
IL-8 4 5 3
IL-9 4 5 3
IL-10 4 5 3
IL-12p40p70 4 5 3
IL-12p70 4 5 3
IL-13 5 5 3
IL-17 5 5 3
RANTES 5 4 2
TIMP-1 5 4 2
TIMP-2 5 4 2
TNF- 3 4 3
sTNF RI 3 4 3
sTNF RII 3 4 3
Numbers indicate fold increase over respective Dox groups. Results are the mean of two membranes for
each treatment and condition. Unchanged cytokines are not shown (supplemental Fig. 2B, available at www.
jneurosci.org as supplemental material). BLC, B-lymphocyte chemoattractant; GM-CSF, granulocyte macrophage
colony stimulation factor; IfN, interferon-; IL, interleukin; RANTES, regulated on activation normal T-cell ex-
pressed and secreted; TIMP, tissue inhibitor of metalloproteinase; sTNF RI and RII, soluble TNF receptors I and II.
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20.6 1.03-tubulin-activated caspase 3cells/mm2 inDox
vs 82.6 1.7 cells/mm2 inDox AICmice ( p	 0.001; n
 10).
Screening of proinflammatory protein levels with a protein array
at day 5 after lesion (Raybiotech) (supplemental Results, avail-
able at www.jneurosci.org as supplementalmaterial) confirmed a
general downregulation by CnA expression (Table 1). Micro-
glia reactivity and macrophage infiltration at the damaged site,
determined by levels of MHCII and number of MHCII and
CD11b cells, was also attenuated (Fig. 3D). Furthermore, as
seen in vitro, the number and the intensity of staining of IGF-I-
immunoreactive astrocytes (IGF-I/GFAP cells) in the vicinity
of the lesion was greater in AIC mice expressing CnA (from
83 16 astrocytes/mm2 inDox to 102 27 astrocytes/mm2 in
Dox; p 	 0.05). Notably, when expression of CnA was al-
lowed in astrocytes after brain trauma,
once the inflammatory cascade is active,
neuronal death was still markedly attenu-
ated. Thus, in AIC mice in which Dox
treatment was discontinued 2 d after in-
jury (Dox mice) to allow CnA expres-
sion (that starts within 24 h of Dox with-
drawal), the number of apoptotic neurons
5 d after injury was markedly reduced,
close to the reduction seen when CnA
expression was allowed before injury
(Dox mice). There were 32  0.7 apo-
ptotic neurons/mm2 in Dox, 17  2.2
neurons inDox, but 75 5.3 neurons in
Dox AIC mice ( p	 0.001 vsDox and
Dox groups; n
 5 per group). InDox
AICmice,microglia reactivity was also sig-
nificantly reduced (Fig. 3D, bottom histo-
grams) ( p	 0.001 vsDox group).
Injection of bacterial endotoxins (LPS)
into the brain is a well establishedmodel of
inflammatory processes associated with
human neurotropic infections (Fass-
bender et al., 2004; Felts et al., 2005). After
brain LPS injection toAICmice, patholog-
ical alterations peaked within 1–3 d and
were resolved 10 d later. We examined the
response toCnA expression 3 d after LPS
challenge and found an attenuated inflam-
matory response when CnA was ex-
pressed. Significantly reduced neuronal
death after LPS injection was seen in AIC
mice without Dox before endotoxic chal-
lenge: 12.0  1.8 3-tubulin/activated
caspase 3 cells/mm2 in Dox vs 63.3 
1.0 3-tubulin/activated caspase 3
cells/mm2 inDox AICmice ( p	 0.001;
n
 10). As seen after brain trauma, mark-
ers of glial reactivity were also reduced in
CnA-expressing AIC mice. These in-
cluded reduced activation of astrocytes
(GFAP/iNOS2) (Fig. 4A), decreased
levels of proinflammatory mediators in
the lesioned area ( p	 0.001 vsAICDox;
n 
 10) (Fig. 4B, Table 1) (supplemental
Fig. 2B, available at www.jneurosci.org as
supplemental material), and reduced mi-
croglia activation (data not shown). Fur-
thermore, systemic administration of LPS
tomimic central inflammatory responses to infection, a common
complication in elderly demented patients (Perry et al., 2003),
resulted also in an attenuated brain inflammatory response when
AIC mice expressed CnA. Five days after intraperitoneal injec-
tion of LPS, the levels of Cox2 and iNOS2 in cortical tissue of AIC
(Dox) mice were reduced compared with AIC mice receiving
Dox in the drinking water (Fig. 4C) (supplemental Fig. 2C, avail-
able at www.jneurosci.org as supplemental material) ( p	 0.001
vs AICDox; n
 10).
Calcineurin inhibits a canonical proinflammatory pathway
in astrocytes
We then explored mechanisms underlying reduced inflamma-
tory responses when calcineurin is activated in astrocytes before
B
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*
Figure 4. Astrocytic calcineurin protects against LPS-induced inflammatory damage. A, Three days after intraparenchymael
injection of LPS, reactive astrocytes (GFAP) in AICmice not treatedwithDox shownegligible iNOS2 immunoreactivity. Scale bar,
100m. B, This was paralleled by a drastic reduction in levels of Cox2 and iNOS2 in the injected area ( p	 0.001 vs AICDox;
n
 10). C, Levels of Cox2 and iNOS2 in cortical tissue of intraperitoneally LPS (iLPS)-injected AIC (Dox) mice were reduced
compared with AIC mice receiving Dox in the drinking water ( p	 0.001 vs AICDox; n
 10 at 3 d after injection). Represen-
tative blots are shown.
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inflammatory challenge. In these studies,
we used an in vitro approach to determine
mechanisms involved at the molecular
level. First, we validated the system by de-
termining whether expression of CnA in
cultured rat astrocytes also ameliorated
the subsequent response to inflammatory
challenge. Indeed, as seen in vivo in AIC
mice, astrocytes expressing CnA before
inflammatory challenge show reduced in-
creases of the inflammatory effectors Cox2
and iNOS2 16 h after LPS (Fig. 5A) or 3 h
after TNF- (data not shown). Other
proinflammatory signals were also inhib-
ited (Table 1). With this system, we next
observed that, in CnA-transfected astro-
cytes, but not in mock-transfected ones,
LPS- or TNF--induced activation of
NFB andNFATwas inhibited even below
basal levels ( p	 0.001 vs CMV astrocytes)
(Fig. 5B). This inhibitory effect of CnA
was not seen in neurons (supplemental
Fig. 3A, available at www.jneurosci.org as
supplemental material). Confirming these
results in rat astrocytes, we found that
NFB and NFAT activity after inflamma-
tory challenge was again inhibited below
basal levels in astrocytes from AIC mice
expressing CnA, i.e., cultured in the ab-
sence of Dox (Fig. 5C).
Mechanisms whereby calcineurin may
block the activation ofNFB andNFATby
proinflammatory stimuli were then ana-
lyzed. As seen previously after IGF-I-
induced activation of calcineurin (Pons
and Torres-Aleman, 2000), expression of
CnA in astrocytes blocked phosphoryla-
tion of IB by TNF- (Fig. 5D). Further-
more, expression of CnA blocked the in-
crease in the levels of NFBp65 and
NFAT4 (an isoform found in astrocytes)
(Jones et al., 2003) elicited by 16 h of expo-
sure to LPS or 3 h after TNF- (data not
shown) in mock-transfected astrocytes
(Fig. 5E) (supplemental Fig. 3B) ( p 	
0.001 vs CMV-transfected astrocytes; n 

6). We next explored mechanism whereby
expression ofCnA results in reduced lev-
els of NFBp65 and NFAT4 after inflam-
matory challenge. First, we inhibited the
proteasome pathway with MG-132 and
found that the effect ofCnA was blocked
(Fig. 5F) (supplemental Fig. 3C, available
at www.jneurosci.org as supplementalma-
terial) ( p	 0.001 vsCnA astrocytes; n

6). This suggested that the proteasome
pathway is involved in the reduction of the
levels of NFBp65 and NFAT4 produced
by CnA. In agreement with this possibil-
ity, we observed that CnA-expressing astrocytes had increased
NFBp65 andNFAT4 complexed with ubiquitin, a protein tag to
the proteasome pathway ( p 	 0.001 vs CMV-transfected astro-
cytes; n
 6) (Fig. 5G) (supplemental Fig. 3D, available at www.
jneurosci.org as supplemental material). At the same time, the
inhibitory action ofCnAwas accompanied by increased associ-
ation of NFAT4 with GATA3 (an isoform of brain tissue)
(Pandolfi et al., 1995) and of NFBp65 with PPAR (Fig. 5H)
Figure 5. Calcineurin inhibits the NFB/NFAT proinflammatory pathway in astrocytes. A, LPS failed to stimulate Cox2 and
iNOS2 in astrocytes expressingCnA. A representative blot is shown (n
 6). B, LPS- or TNF--induced activation of NFB and
NFAT was abrogated inCnA-transduced astrocytes. The activity of these transcription factors was inhibited after exposure to
LPS/TNF- inCnA-expressingastrocytes. Note that expressionofCnA inunstimulatedastrocytes reduced theactivity ofNFB
andNFAT. CMV,Astrocytes transfectedwith the empty vector;CnA, astrocytes transfectedwith constitutively active calcineurin;
CMVNFB or NFAT, mock-transfected astrocytes expressing the gene-reporter system for either transcription factor;
CnANFB or NFAT, CnA-transfected astrocytes expressing the gene-reporter system. ***p	 0.001 versus respective
controls (n
 6). C, In astrocytes from AIC mice, activation of NFB and NFAT after LPS (left) or TNF- (right) was regulated by
Dox, confirming that expression ofCnA suppresses it. **p	 0.01 and ***p	 0.001 versus respective controls.D, Expression of
CnA blocks phosphorylation of IB induced by TNF- (20 ng/ml, 15min of exposure, representative blot). Mock-transfected
cultures received the pCMV vector. E, Exposure of mock-transfected astrocytes to LPS elicited an increase in NFBp65 (left) and
NFAT4 (right) protein levels 16 h later. This increasewas significantly attenuated in astrocytes expressingCnA. F, The inhibitory
effect ofCnA on NFBp65/NFAT4 levels was blocked by the proteasome inhibitory drug MG-132 (MG). G,CnA-expressing
astrocytes have significantly increasedNFBp65 andNFAT4 complexedwith ubiquitin. Immunoprecipitationwith anti-NFBp65
or anti-NFAT4 followed by blotting with anti-ubiquitin (top blots). H, Astrocytes transduced withCnA had increased levels of
NFBp65/PPAR and NFAT/GATA3 compared with control astrocytes. Immunoprecipitation with anti-PPAR and anti-GATA3
followed by blottingwith either anti-NFBp65 or anti-NFAT4 (top blots). The opposite immunoprecipitations gave similar results
(data not shown). In all cases, levels of-actin or the respective immunoprecipitated protein were determined for protein load
(bottom blots). Representative blots (of 6 for each experiment) are shown. All changes were significantly different (see Results).
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(supplemental Fig. 3E, available at www.jneurosci.org as supple-
mental material) ( p 	 0.001 vs CMV astrocytes; n 
 6). These
two transcription factors modulate the activity of NFB and
NFAT, respectively (Avni et al., 2002; Bailey and Ghosh, 2005).
Similar changes were seen in astrocytes obtained from AIC mice
and cultured in the presence or absence of Dox (data not shown).
Astrocyte calcineurin is recruited by both proinflammatory
and anti-inflammatory signals
Althoughour results indicated that active calcineurin counteracts
a subsequent inflammatory stimulus, this phosphatase is known
to participate in inflammatory responses
(Staruch et al., 1998). Indeed, as seen in
other cell types, in quiescent wt astrocytes,
calcineurin is activated by LPS and TNF-
(Fig. 6A). Moreover, when endogenous
calcineurin is depleted in wt astrocytes by
transfection of an siRNA against cal-
cineurin, the production of inflammatory
mediators such as iNOS2 or Cox2 in re-
sponse to LPS is abrogated (Fig. 6B). LPS
and TNF- also stimulated the activity of
the proinflammatory transcription factors
NFB and NFAT and in a calcineurin-
dependent manner, as evidenced by its
blockade with CsA (Fig. 6C).
However, an anti-inflammatory factor
such as IGF-I, which inhibits TNF--
stimulated NFB in astrocytes (Pons and
Torres-Aleman, 2000), also enhanced cal-
cineurin activity in wt astrocytes (Fig. 6A).
At the same time, IGF-I was able to inhibit
the increase in NFB and NFAT activity
after inflammatory stimuli (Fig. 6D). That
activation of calcineurin in astrocytes is es-
sential for the neuroprotective actions of
IGF-I against inflammationwas evidenced
by the fact that IGF-I rescued neurons of
TNF--induced death (Fig. 6E) or block
neuronal production of ROS after TNF-
(Fig. 6F) only when astrocytes were
present. A similar protective effect of IGF-I
was seen after LPS (data not shown). Fur-
thermore, calcineurin was essential for
IGF-I neuroprotection because cyclospor-
ine A inhibited its actions (Fig. 6E). Be-
cause IGF-I is found in reactive astrocytes
in brain lesions in which inflammation oc-
curs (supplemental Fig. 3F, available at
www.jneurosci.org as supplemental mate-
rial), it may activate astrocyte calcineurin
during brain injury.
Discussion
Glial cells are a rich source of trophic sig-
nals for neurons, and its potential use as
therapeutic targets in neurodegenerative
diseases has already been outlined
(Ranaivo et al., 2006). However, a better
knowledge of the pathways involved in
glia-to-neuron protective communication
is needed before we can properly address
this goal. Our present observations indi-
cate that the phosphatase calcineurin in astrocytes modulates
neuronal damage associated with inflammation, a common con-
dition in the neurodegenerative process (Minghetti, 2005). In-
triguingly, in brain diseases in which inflammation is involved
such as Alzheimer’s disease (Mrak and Griffin, 2005) or amyo-
trophic lateral sclerosis (Weydt et al., 2002), calcineurin activity
has been reported to be abnormally low (Ladner et al., 1996; Ferri
et al., 2001), whereas in situ generation of constitutively active
calcineurin is neuroprotective in brain ischemia (Shioda et al.,
2006).
Although the role of calcineurin in inflammation has long
Figure 6. Astrocytic calcineurin participates in proinflammatory and in anti-inflammatory signaling. A, In wt astrocytes,
calcineurin activitywas incremented by proinflammatory stimuli such as LPS/TNF- and by neuroprotective signals such as IGF-I.
**p	0.01 and***p	0.001 versus control.B, In astrocytes transfectedwith a calcineurin-specific siRNA (CnA3), the production
of inflammatory mediators such as iNOS2 or Cox2 in response to inflammatory challenge (LPS) was abrogated in parallel to
inhibited calcineurin levels. Controls, Astrocytes transfected with non-sense siRNA; GAPDH, astrocytes transfected with GAPDH
siRNA. Note that, although levels of this protein are depleted, the response to LPS/TNF- remains intact. Representative blots are
shown (n
 6). Other CnA siRNAs tested gave similar results (data not shown). C, LPS/TNF--stimulated activity of NFB and
NFAT was abrogated in the presence of CsA. NFB and NFAT denote transfection of astrocytes with NFB and NFAT reporters,
respectively. **p	 0.01 and ***p	 0.001 versus untreated controls (shown in left white bars). D, IGF-I inhibited the increase
induced by LPS or TNF- in the activity of NFB and NFAT. ***p	 0.001 versus unstimulated controls (n
 6). ***p	 0.001
versus unstimulated controls. E, IGF-I protected neurons against TNF--induced death only in the presence of astrocytes. This
effect was blocked by CsA. Neurons were exposed to TNF- overnight. F, Production of ROS after LPS challenge was blocked by
IGF-I only in the presence of astrocytes. *p	 0.05 and ***p	 0.001 versus respective controls (n
 6).
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been known and its inhibitors are used in
the clinic (Shanley, 2002), its concomitant
involvement in anti-inflammatory signal-
ing was not documented (Fig. 7). This am-
bivalent mechanism of astrocyte cal-
cineurin, reminiscent of that reported for
CD14 in immune cell responses (Devitt et
al., 1998), may help explain the long-held
notion that an interplay between proin-
flammatory and anti-inflammatory sig-
nals dictates the outcome of the inflamma-
tory process and, ultimately, its associated
neuronal loss (Wyss-Coray and Mucke,
2002). Indeed, signals that activate cal-
cineurin, including neuroprotective fac-
tors such as IGF-I, together with cytokines
such as TNF- are present in inflamma-
tory lesions in a distinct time-dependent
manner. Whereas TNF- increases within
hours after damage (Yin et al., 2003),
IGF-I levels peak after days (Beilharz et al.,
1998). This pattern of activation would
theoretically allow a calcineurin-
dependent termination of the acute in-
flammatory phase and resultant genera-
tion of ROS by an anti-inflammatory
action of IGF-I and other protective sig-
nals. Other signals are clearly involved be-
cause inhibition of the action of
calcineurin-induced IGF-I is not sufficient
to abrogate the neuroprotective actions of
calcineurin-expressing astrocytes. Among
these, SOD appears as a likely candidate
because its production was enhanced, and
this can be related to ROS inhibition and
neuroprotection because SOD is a potent
free radicals inhibitor and neuroprotective
signal.
In initial stages of the inflammatory
process, calcineurin will be activated by
TNF- (and othermediators of inflamma-
tion).Once IGF-I (and other neuroprotec-
tive mediators such as SOD) produced mostly by activated mi-
croglia (and other local, i.e., astrocytes, and peripheral sources)
start to accumulate at the lesion site, calcineurin will be further
stimulated (Fig. 6A). This IGF-I activation of already active cal-
cineurinwould result in cancellation of the inflammatory cascade
and potentiation of the neuroprotective pathway (Fig. 7). The
fact that transgenic expression of constitutively active calcineurin
both in vivo and in vitro results also in neuroprotection suggests
that a certain level of calcineurin activity (compare the levels of
active calcineurin in Figs. 1A and 6A) is required for neuropro-
tection. Although the initial calcineurin-dependent release of
proinflammatory mediators after insult by astrocytes is consid-
ered to be beneficial, its subsequent harnessing by calcineurin-
dependent anti-inflammatory pathways may be critical to avoid
maladaptive responses.
Previous reports indicated both beneficial and detrimental
actions of calcineurin in the response of astrocytes to insults,
including inflammation (Pons and Torres-Aleman, 2000; Norris
et al., 2005). Gene expression analysis of mixed astrocyte–neuro-
nal cultures transduced withCnA showed a reactive/inflamma-
tory astrocyte phenotype. However, expression of CnA in
mixed cultures also induced neuroprotective signals, and neuro-
nal proapoptotic genes were downregulated (Norris et al., 2005).
Collectively, it seems that activation of calcineurin in resting as-
trocytes leads to an inflammatory phenotype, whereas its activa-
tion in stimulated astrocytes (after stimuli such as inflammatory
mediators) results in abrogation of inflammatory cascades. This
cell-context-dependent pattern of calcineurin signaling, a com-
mon feature of intracellular signaling pathways (Natarajan et al.,
2006), may help understand the apparently contradictory obser-
vation that calcineurin can regulate NFAT/NFB activity in op-
posite ways (Rao et al., 1997; Biswas et al., 2003; Kim et al., 2004;
Martinez-Martinez et al., 2006). Calcineurin is also known to
play opposing roles in apoptotic responses, depending on cell
context and type of stimulus. Indeed, modulation of calcineurin
in astrocytes affects their response to apoptotic stimuli (Kamin-
ska et al., 2004), which could theoretically explain its neuropro-
tective effect because astrocytes are essential protective partners
for neurons (Takuma et al., 2004). However, the fact that the
proinflammatory stimuli used in the present study did not pro-
duce astrocyte death makes it unlikely that astrocyte calcineurin
protected neurons by modulating astrocyte apoptosis.
Resolution
Calcineurin
NFκB/NFAT
Inflammatory
cascade
Calcineurin
NFκB/NFAT
Neuroprotective
cascade
Progression
Inflammatory challenge
Calcineurin
NFκB/NFAT
Astrocyte
Neuron
Recruitment of para/autocrine
anti-inflammatory signals
(IGF-I, SOD…etc) 
Activation of para/autocrine
inflammatory cascades
(TNF-α..etc)
Initiation
Figure 7. Stages of the neuroinflammatory process in which astrocyte calcineurin may participate. Initiation, Inflammatory
signals set in motion by the neuropathological process activate calcineurin, which in turn activate the canonical NFB/NFAT
pathway. Activation of local and peripheral proinflammatory mechanisms together with the recruitment of autocrine and para-
crine neuroprotective mediators follows. The time course of this simultaneous anti-inflammatory and proinflammatory cascade
may be critical to the eventual outcome of the inflammatory response. Both agonistic and antagonistic inflammatory signals are
produced by reactive astrocytes and microglia, damaged neurons and activated endothelia, and eventually from peripheral cells
recruited to the lesion site. Resolution, If already activated calcineurin is stimulated by signals such as IGF-I, a neuroprotective
network is activated; Progression, if calcineurin continues tobeactivatedby inflammatory signals, the inflammationproceeds and
neurons die. Both phases may be reversibly interrelated depending on the time course of the pathological process. Mechanisms
whereby calcineurin is recruited toward either inflammation or neuroprotection, which involve differential interactions with
transcription factors such as PPAR andGATA3or proteasomedegradation andwhich dependon theupstreamsignal stimulating
calcineurin, warrant additional analysis.
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Although the routes involved in stimulation of NFAT and
NFB are well described, the pathways involved in their inactiva-
tion are less known. The present results suggest that calcineurin
inhibits NFB by dephosphorylation of nuclear factor B inhib-
itor (IB) and interactions with PPAR, and NFAT through in-
teractions with GATA. Both transcription factors have been
shown previously to interact with NFAT and NFB, respectively
(Chinetti et al., 1998; Wada et al., 2002). Intriguingly, recent
evidence indicates that not only calcineurin (see above) but also
PPAR activity is diminished in Alzheimer’s disease patients
(Sastre et al., 2006). Calcineurinmay also direct NFAT andNFB
to the proteasome pathway because lower levels of both tran-
scription factors together with increased association to ubiquitin
was observed in the presence of CnA. Our results also confirm
the stimulatory role of calcineurin on neuroprotective signals
such as SOD and IGF-I (McCall et al., 2003; Norris et al., 2005),
providing a conceptual framework to understand the contribu-
tion of astroglia to neuronal death in diseases such as amyotro-
phic lateral sclerosis (Clement et al., 2003), in which these neu-
roprotective signals are involved (Wilczak et al., 2003; Turner et
al., 2005).
Altogether, it seems that calcineurin plays a dual role in acti-
vating proinflammatory cascades in response to proinflamma-
tory signals such as TNF- or canceling them and at the same
time promoting neuroprotection in response to trophic signals
such as IGF-I. At any rate, the pathways underlying this dual
action of calcineurin, which probably involves interactions with
scaffolding andmodulatory proteins (Klauck et al., 1996; Fuentes
et al., 2000; Abbasi et al., 2006), and release of various neuro-
modulators warrant additional studies.
In summary, astrocyte calcineurin may constitute a key ele-
ment in the process whereby an acute inflammatory response
progresses toward a neuroprotective effect and is resolved or de-
velops into a sustained insult.
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